drugset
drugset / Trial / NCT05703984

A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting Conditions

NCT05703984 ↗

Phase 1 Unknown 50 enrolled GC Biopharma Corp
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and pharmacokinetics of oral administration of GC2129A in fasting conditions to healthy adult volunteers.

Timeline

Start
2023-01-17
Primary completion
2023-04-19
Completion
2023-04-19

Drugs

EvaluationDrugModalityDoseRoute
Subject GC2129A Unknown — Oral
Subject Linagliptin Small molecule 5 mg —
Subject Metformin Small molecule 1000 mg —

Indications

No indication recorded.